BioCentury
ARTICLE | Company News

Alchemgen Therapeutics Inc., EntreMed, The Children's Medical Center Corp. deal

February 9, 2004 8:00 AM UTC

ENMD transferred to Alchemgen and the Children's Medical Center all rights to its endostatin and angiostatin therapeutic protein programs. Alchemgen will have rights in Asia, while Children's will have rights elsewhere. ENMD will receive upfront and future cash payments plus royalties, including 20% of proceeds from any license that Children's grants related to the products. Endostatin is a protein fragment of collagen XVIII to treat metastatic melanoma, and angiostatin is an angiogenesis inhibitor cleavage product of the protein plasminogen to treat non-small cell lung cancer (NSCLC). Both are in Phase II development...